Last reviewed · How we verify
SB683699
At a glance
| Generic name | SB683699 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients (PHASE1)
- Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis (PHASE2)
- Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis (PHASE2)
- Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease (PHASE2)
- Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB683699 CI brief — competitive landscape report
- SB683699 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI